These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26237907)

  • 1. [Radiologic side effects of cancer therapy].
    Beule A; Tarkkanen M
    Duodecim; 2015; 131(5):448-56. PubMed ID: 26237907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug-induced interstitial lung diseases].
    Bonniaud P; Georges M; Favrolt N; Camus P
    Rev Prat; 2014 Sep; 64(7):951-6. PubMed ID: 25362778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse reactions to oncologic drugs: spontaneous reporting and signal detection.
    Tuccori M; Montagnani S; Capogrosso-Sansone A; Mantarro S; Antonioli L; Fornai M; Blandizzi C
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):61-75. PubMed ID: 25363790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Organ toxicity of medicinal tumor therapy: morphological correlates].
    Sedlaczek O; Grüllich C; Röthke M; Schlemmer HP; Kauczor HU
    Radiologe; 2013 Apr; 53(4):329-35. PubMed ID: 23536030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Novel oral anticancer drugs: a review of adverse drug reactions, interactions and patient adherence].
    Bartal A; Mátrai Z; Szucs A; Belinszkaja G; Langmár Z; Rosta A
    Orv Hetil; 2012 Jan; 153(2):66-78. PubMed ID: 22217686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse drug events in critically ill patients with cancer: incidence, characteristics, and outcomes.
    Nazer LH; Hawari F; Al-Najjar T
    J Pharm Pract; 2014 Apr; 27(2):208-13. PubMed ID: 24319079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving the goals of effective, safe, and individualized cancer care.
    Roberts SA; Karnes EK; Allen JD; Benner JS; Sigal EV; McClellan M
    Clin Cancer Res; 2011 Nov; 17(21):6632-3. PubMed ID: 22046023
    [No Abstract]   [Full Text] [Related]  

  • 8. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follow-Up on the Use of Machine Learning in Clinical Quality Assurance: Can We Detect Adverse Event Under-Reporting in Oncology Trials?
    Ménard T; Koneswarakantha B; Rolo D; Barmaz Y; Popko L; Bowling R
    Drug Saf; 2020 Mar; 43(3):295-296. PubMed ID: 31834590
    [No Abstract]   [Full Text] [Related]  

  • 10. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms.
    Abramson RG; Abramson VG; Chan E; Horn L; Keedy VL; Pao W; Sosman JA
    AJR Am J Roentgenol; 2013 Mar; 200(3):475-83. PubMed ID: 23436834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cancer diagnosis: no need to despair].
    Heinrich B
    MMW Fortschr Med; 2015 Aug; 157(14):38. PubMed ID: 26289883
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of uncommon chemotherapy-induced emergencies.
    Morgan C; Tillett T; Braybrooke J; Ajithkumar T
    Lancet Oncol; 2011 Aug; 12(8):806-14. PubMed ID: 21276754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of pharmacogenomics/biomarker-guided clinical trials for regulatory approval of anti-cancer drugs in Japan.
    Ishiguro A; Yagi S; Uyama Y
    J Hum Genet; 2013 Jun; 58(6):313-6. PubMed ID: 23657427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting patient's perception of anticancer treatments side-effects: an observational study.
    Russo S; Cinausero M; Gerratana L; Bozza C; Iacono D; Driol P; Deroma L; Sottile R; Fasola G; Puglisi F
    Expert Opin Drug Saf; 2014 Feb; 13(2):139-50. PubMed ID: 24073801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. News products to avoid.
    Prescrire Int; 2014 Apr; 23(148):105. PubMed ID: 24860903
    [No Abstract]   [Full Text] [Related]  

  • 16. Imaging of acute and subacute toxicities of cancer therapy in children.
    Chavhan GB; Babyn PS; Nathan PC; Kaste SC
    Pediatr Radiol; 2016 Jan; 46(1):9-20; quiz 6-8. PubMed ID: 26459011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Organ-specific fungal infections as a complication of treatment of children with cancer. A single centre observation].
    Kajdas L; Szczepański T; Trzeszkowska-Rotkegel S; Bubała H; Sońta-Jakimczyk D
    Med Wieku Rozwoj; 2007; 11(3 Pt 2):331-5. PubMed ID: 18663276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complications of oncologic therapy in the abdomen and pelvis: a review.
    Ganeshan DM; Salem U; Viswanathan C; Balachandran A; Garg N; Silverman P; Bhosale P
    Abdom Imaging; 2013 Feb; 38(1):1-21. PubMed ID: 22644726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Supportive therapy and management of side effects in dermato-oncology].
    von Dücker L; Hüning S; Kähler K; Terheyden P; Nashan DRT
    Hautarzt; 2019 Dec; 70(12):975-988. PubMed ID: 31720719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity and costs of toxicity associated with new cancer drugs: international implications.
    Hermanson T; Norris LB; Bian J; Sartor O; Bennett CL
    J Clin Oncol; 2014 Nov; 32(32):3591-2. PubMed ID: 25267755
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.